ストックスクリーナーアプリを入手
0.4601
3.39%
0.0151
前日終値:
$0.445
開ける：
$0.45
24時間の取引高:
235.62K
Relative Volume:
0.50
時価総額：
$28.53M
収益：
-
当期純損益:
$-151.16M
株価収益率:
-0.1549
EPS:
-2.97
ネットキャッシュフロー:
$-130.08M
1週間 パフォーマンス:
+1.66%
1か月 パフォーマンス:
-17.05%
6か月 パフォーマンス:
-74.58%
1年 パフォーマンス:
-91.78%
1日の値動き範囲:
$0.4452
$0.468
1週間の範囲:
$0.404
$0.468
52週間の値動き範囲:
$0.404
$8.78
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
名前
Alx Oncology Holdings Inc
セクター
電話
650-466-7125
住所
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
ALXO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.4601 | 28.53M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-06 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2024-03-08 | ダウングレード | Stifel | Buy → Hold |
| 2023-12-08 | アップグレード | Jefferies | Hold → Buy |
| 2021-12-22 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-30 | 開始されました | Stifel | Buy |
| 2021-05-05 | 再開されました | Credit Suisse | Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-04-06 | 開始されました | UBS | Buy |
| 2021-02-10 | 開始されました | H.C. Wainwright | Buy |
| 2020-08-11 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-08-11 | 開始されました | Credit Suisse | Outperform |
| 2020-08-11 | 開始されました | Jefferies | Buy |
| 2020-08-11 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Alx Oncology Holdings Inc (ALXO) 最新ニュース
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Rating of “Moderate Buy” by Analysts - Defense World
ALX Oncology Confirms Directors at Annual Meeting - TipRanks
ALX Oncology reports annual meeting results By Investing.com - Investing.com Nigeria
ALX Oncology reports annual meeting results - Investing.com
Cantor Fitzgerald Weighs in on ALX Oncology FY2026 Earnings - Defense World
ALX Oncology (NASDAQ:ALXO) Downgraded to “Sell” Rating by Wall Street Zen - Defense World
Nuveen Asset Management LLC Has $275,000 Holdings in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Acquired by Two Sigma Investments LP - Defense World
Bank of America Corp DE Grows Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Acquired by Deutsche Bank AG - Defense World
Northern Trust Corp Acquires 23,324 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference - GlobeNewswire
ALX Oncology to Present at the Jefferies 2025 Global Healthcare Conference | ALXO Stock News - GuruFocus
ALX Oncology Management to Showcase Novel Cancer Treatment Advances at Major Jefferies Healthcare Conference - Stock Titan
D. E. Shaw & Co. Inc. Decreases Stock Position in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
H.C. Wainwright maintains ALX Oncology stock Buy rating By Investing.com - Investing.com India
H.C. Wainwright maintains ALX Oncology stock Buy rating - Investing.com
Analysts Offer Insights on Healthcare Companies: Tvardi Therapeutics (TVRD) and ALX Oncology Holdings (ALXO) - The Globe and Mail
UBS Group Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
Pre-market Movers: VIGL, CVM, KDLY, VTAK... - RTTNews
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ALXO: UBS Maintains 'Buy' Rating, Lowers Price Target | ALXO Sto - GuruFocus
ALXO: UBS Maintains 'Buy' Rating, Lowers Price Target | ALXO Stock News - GuruFocus
UBS Adjusts Price Target on ALX Oncology Holdings to $1 From $1.20, Maintains Buy Rating - marketscreener.com
ALX Oncology presents preclinical data, plans for ALX-2004 - BioWorld MedTech
UBS Adjusts Price Target for ALX Oncology (ALXO) to $1 | ALXO St - GuruFocus
UBS Adjusts Price Target for ALX Oncology (ALXO) to $1 | ALXO Stock News - GuruFocus
Transcript : ALX Oncology Holdings Inc.Special Call - marketscreener.com
ALX Oncology : Investor Presentation ALX2004 Webcast May 20 2025 Final (2a4ce1) - marketscreener.com
ALX Oncology Holdings Inc. Highlights Differentiated Design, Preclinical Data and Development Plans for EGFR-Targeted ADC, ALX2004, in R&D Webcast Event - marketscreener.com
ALXO Unveils Advanced Antibody-Drug Conjugate ALX2004 for Tumor Treatment | ALXO Stock News - GuruFocus
ALX Oncology Highlights Differentiated Design, Preclinical - GlobeNewswire
First-in-Class Cancer Drug: ALX Oncology's Novel EGFR-ADC Gets FDA Green Light for Clinical Trials - Stock Titan
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Cubist Systematic Strategies LLC - Defense World
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EG - GuruFocus
ALX Oncology to Host R&D Webcast Event Highlighting its - GlobeNewswire
ALX Oncology to Host R&D Webcast Event Highlighting its Novel EGFR Targeting Antibody-Drug Conjugate, ALX2004, on May 20, 2025 - Stock Titan
HC Wainwright Issues Pessimistic Forecast for ALX Oncology (NASDAQ:ALXO) Stock Price - Defense World
ALXO Stock: HC Wainwright & Co. Lowers Price Target | ALXO Stock News - GuruFocus
ALX Oncology Reports Q1 2025 Financial Results - TipRanks
ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
ALXO Advances Cancer Therapy Focus and Pipeline Development | AL - GuruFocus
ALXO Advances Cancer Therapy Focus and Pipeline Development | ALXO Stock News - GuruFocus
ALX ONCOLOGY Earnings Results: $ALXO Reports Quarterly Earnings - Nasdaq
Financial Health Check: Examining Alx Oncology Holdings Inc (ALXO)’s Key Ratios - DWinneX
ALX Oncology Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ALX Oncology to Report First Quarter 2025 Financial Results on M - GuruFocus
ALX Oncology Holdings Inc expected to post a loss of 46 cents a shareEarnings Preview - TradingView
Will ALXO Make A Comeback In July? - RTTNews
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - The Manila Times
ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 | ALXO Stock News - GuruFocus
Alx Oncology Holdings Inc (ALXO) 財務データ
収益
当期純利益
現金流量
EPS
Alx Oncology Holdings Inc (ALXO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pinto Shelly | SVP, FINANCE AND CAO |
Feb 19 '25 |
Sale |
1.15 |
550 |
633 |
87,352 |
| Pons Jaume | PRESIDENT & CSO |
Feb 19 '25 |
Sale |
1.15 |
1,326 |
1,525 |
579,388 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Feb 19 '25 |
Sale |
1.15 |
2,159 |
2,483 |
170,270 |
| Pinto Shelly | Interim CFO |
Jan 06 '25 |
Sale |
1.80 |
2,221 |
3,998 |
87,902 |
| Pinto Shelly | Interim CFO |
Dec 30 '24 |
Sale |
1.58 |
1,426 |
2,253 |
90,123 |
| Pons Jaume | PRESIDENT & CSO |
Dec 30 '24 |
Sale |
1.58 |
10,796 |
17,060 |
580,714 |
| Hemrajani Rekha | Director |
Dec 02 '24 |
Buy |
1.55 |
30,000 |
46,404 |
33,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 14 '24 |
Sale |
2.58 |
564 |
1,455 |
91,549 |
| Randolph Sophia | CHIEF MEDICAL OFFICER |
Aug 14 '24 |
Sale |
2.58 |
1,365 |
3,522 |
325,711 |
| Pons Jaume | PRESIDENT & CSO |
Aug 14 '24 |
Sale |
2.58 |
1,937 |
4,997 |
591,510 |
0.68%
0.50%
大文字化:
|
ボリューム (24 時間):